These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11180042)

  • 1. An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol.
    Chiou WL; Ma C; Chung SM; Wu TC
    Clin Pharmacol Ther; 2001 Jan; 69(1):79-81. PubMed ID: 11180042
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should pharmacotherapy of digoxin be reviewed in male patients with heart failure in the case of association with carvedilol?
    Souza FC; Neri JS; Marques EB; Barros RB; Scaramello CB
    Int J Cardiol; 2015 Jul; 191():4-6. PubMed ID: 25957928
    [No Abstract]   [Full Text] [Related]  

  • 4. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
    Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
    Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition.
    Weiss M; Sermsappasuk P; Siegmund W
    J Clin Pharmacol; 2012 Mar; 52(3):381-7. PubMed ID: 21343347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
    Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
    Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil.
    Gramatté T; Oertel R
    Clin Pharmacol Ther; 1999 Sep; 66(3):239-45. PubMed ID: 10511059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carvedilol increases the systemic bioavailability of oral digoxin.
    De Mey C; Brendel E; Enterling D
    Br J Clin Pharmacol; 1990 Apr; 29(4):486-90. PubMed ID: 1970265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
    Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
    Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
    Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
    Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
    Peng SX; Ritchie DM; Cousineau M; Danser E; Dewire R; Floden J
    J Pharm Sci; 2006 Sep; 95(9):1984-93. PubMed ID: 16850393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro.
    Cornaire G; Woodley JF; Saivin S; Legendre JY; Decourt S; Cloarec A; Houin G
    Arzneimittelforschung; 2000 Jun; 50(6):576-9. PubMed ID: 10918954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin.
    Ghanem CI; Gómez PC; Arana MC; Perassolo M; Delli Carpini G; Luquita MG; Veggi LM; Catania VA; Bengochea LA; Mottino AD
    J Pharmacol Exp Ther; 2006 Sep; 318(3):1146-52. PubMed ID: 16740618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans.
    Drescher S; Glaeser H; Mürdter T; Hitzl M; Eichelbaum M; Fromm MF
    Clin Pharmacol Ther; 2003 Mar; 73(3):223-31. PubMed ID: 12621387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans.
    Oswald S; Terhaag B; Siegmund W
    Handb Exp Pharmacol; 2011; (201):403-47. PubMed ID: 21103977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin.
    Pathak SM; Udupa N
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):202-14. PubMed ID: 20238375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.
    Igel S; Drescher S; Mürdter T; Hofmann U; Heinkele G; Tegude H; Glaeser H; Brenner SS; Somogyi AA; Omari T; Schäfer C; Eichelbaum M; Fromm MF
    Clin Pharmacokinet; 2007; 46(9):777-85. PubMed ID: 17713975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ketoconazole on digoxin absorption and disposition in rat.
    Salphati L; Benet LZ
    Pharmacology; 1998 Jun; 56(6):308-13. PubMed ID: 9654217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport.
    Amioka K; Kuzuya T; Kushihara H; Ejiri M; Nitta A; Nabeshima T
    J Pharm Pharmacol; 2007 Oct; 59(10):1383-7. PubMed ID: 17910813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.
    Verstuyft C; Strabach S; El-Morabet H; Kerb R; Brinkmann U; Dubert L; Jaillon P; Funck-Brentano C; Trugnan G; Becquemont L
    Clin Pharmacol Ther; 2003 Jan; 73(1):51-60. PubMed ID: 12545143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.